Raphael Pharmaceutical Inc. (RAPH)
Raphael Pharmaceutical Inc. operates in the Drug Manufacturers - Specialty & Generic industry of the Healthcare sector, headquartered in Jaffa, TA, IL. The stock last traded at $1.40, up 0.00% on the session, giving a market capitalisation of $28.2M. On trailing twelve-month figures it carries a trailing P/E of -25.69, a net margin of 0.0%. Its beta of 1.90 implies it has historically moved more than the broad market.
Raphael Pharmaceutical Inc. operates as a biopharmaceutical firm, concentrating its efforts on discovering and clinically developing novel therapeutic solutions. These treatments primarily leverage cannabinoids and are designed to enhance patients' quality of life. Currently, the company's leading investigational drug candidate is being advanced for the management of rheumatoid arthritis. Furthermore, Raphael Pharma plans to broaden its pipeline to include more cannabinoid-based medicines aimed at various cancer types and other autoimmune conditions. The company's corporate headquarters are situated in Tel Aviv-Jaffa, Israel.
Raphael Pharmaceutical Inc. is most often compared with the following Healthcare names: